Do the stem cells need to match my blood type? Can my body reject them?

Rejection in the sense of an organ transplant is not expected with this type of treatment. Large safety reviews of mesenchymal stem cells given into the bloodstream report that the most frequent related event is a transient fever, which resolves on its own. What some patients experience is not rejection but a smaller response than expected, since results vary from person to person.

When patients learn that our cells come from a donor, two questions come up almost immediately: "Do I need a compatible donor?" and "Will my body reject the cells?" Both are reasonable, because most people know that blood transfusions and organ transplants require matching. This guide explains why mesenchymal stem cells are different, what the research says and what reactions, if any, you can expect.

Why blood transfusions and transplants need matching

Your immune system recognizes "self" and "non-self" through molecules on the surface of cells:

• Blood group antigens (ABO and Rh) are on red blood cells. If you receive blood of an incompatible type, your antibodies attack it. This is why transfusions require blood type matching.
• HLA molecules (human leukocyte antigens) are on most cells. They are the main reason organs and bone marrow transplants require tissue typing and, often, lifelong medication to prevent rejection.

Why mesenchymal stem cells are different

Mesenchymal stem cells (MSCs) behave differently from red blood cells and from organ tissue:

• They are not red blood cells. MSCs do not carry the ABO blood group antigens that determine transfusion compatibility in the way red blood cells do. Blood type does not determine whether you can receive them.
• They carry low levels of HLA class I and lack HLA class II (HLA-DR). HLA-DR is one of the molecules that most strongly activate the immune response. In fact, the international definition of MSCs, published by the International Society for Cell and Gene Therapy (ISCT), requires that they do not express HLA-DR.
• They do not express co-stimulatory molecules that immune cells need to launch a full attack.
• They release signals that calm the immune response. MSCs secrete factors that help regulate inflammation and modulate immune cells. This is one of the reasons why they are used in inflammatory and autoimmune conditions.

Our example certificate of analysis shows these properties in practice: the cells test negative for HLA-DR and for blood and immune cell markers, such as CD34, CD45, CD14, CD11b and CD19.

"Immunoprivileged" or "immune evasive"?

You may read that umbilical cord MSCs are "immunoprivileged" or "universal." This means that they can be given from a donor without matching. Scientists also use a more precise term: a review in Nature Biotechnology titled "Mesenchymal stem cells: immune evasive, not immune privileged" explains that MSCs are not invisible to the immune system, but that their low immunogenicity and their immune-modulating signals allow them to be well tolerated when given from a donor. In practice, both terms lead to the same conclusion for patients: no blood type or DNA match is required.

Why umbilical cord MSCs are a good choice for donor use

Umbilical cord MSCs have additional advantages:

• Young cells: they come from newborn tissue, with strong signaling and growth capacity.
• Low immunogenicity: a review in the World Journal of Stem Cells on umbilical cord MSCs describes their immunomodulatory capacity and their potential for use from a donor.
• No harvest from your body: because the cells come from a carefully screened donor, you do not need a bone marrow or fat extraction, and the treatment does not depend on the age or quality of your own stem cells.

Donor cells versus your own cells

Some clinics use autologous cells, taken from the patient's own fat or bone marrow. Because they are your own, they do not raise compatibility questions, but they require an extraction procedure, and their quality depends on your age and health. Our treatments use allogeneic cells from donated umbilical cord tissue. Thanks to their low immunogenicity, these donor cells can be used without matching, and they offer young, consistent cells that have passed donor screening and quality control before release. For patients, this means no harvest procedure, a defined dose and the same quality standards for every batch.

What the safety research shows

Two large reviews have analyzed the safety of mesenchymal stem cells given into the bloodstream, the route where the cells meet the immune system most directly:

• A 2020 systematic review and meta-analysis in EClinicalMedicine pooled clinical trials with thousands of patients and reported that intravascular MSCs continue to appear safe. The most frequently associated event was a transient fever.
• An updated 2026 systematic review and meta-analysis in Stem Cells Translational Medicine, focused on umbilical cord-derived MSCs given intravascularly, reached consistent conclusions about safety.

These findings come from patients who received donor cells without matching, which supports the practice of using umbilical cord MSCs without blood type or DNA compatibility testing.

What reactions can occur?

Rejection like an organ transplant is not expected with this treatment. Some patients experience mild, temporary reactions, such as:

• A transient fever or a feeling of tiredness after an IV infusion, usually resolving within a day or two.
• Soreness, swelling or a feeling of fullness in a treated joint after a direct injection, which is part of the normal response to the procedure and to the PRP.
• Mild discomfort at the IV site, like any IV.

These reactions are monitored during your night at our facilities under nursing and medical care. The team can give you medication for discomfort if needed, and you receive written aftercare instructions before discharge.

Rejection versus "not responding"

In the answers we give to our patients, we explain that what some people describe as "rejection" is usually something different: a patient who does not feel as much improvement as expected after a few months. This is not an immune attack against the cells. It reflects the fact that results vary between patients, depending on the condition, its stage, age, general health, activity level and how the body responds to regenerative signals. Most patients notice gradual changes over weeks to months, and the follow-up program helps track your progress.

Do I need any immune tests before treatment?

No compatibility tests are needed. On your arrival day, you have routine laboratory tests, including a complete blood count, a metabolic panel, urinalysis and tumor markers. These help the doctor confirm that you are a good candidate for treatment, but they are not used to match you with a donor.

Special situations

Tell the medical team if you:

• Have an autoimmune condition, such as rheumatoid arthritis, lupus or multiple sclerosis.
• Take immunosuppressive medication or biologic drugs.
• Have had a transplant.
• Have a history of severe allergic reactions.

These situations do not automatically exclude you, but the doctor needs to know about them to plan your treatment safely.

Common questions

My blood type is rare. Can I still receive the cells? Yes. Blood type does not matter for this treatment, whether it is common or rare.

Will I need anti-rejection medication? No. Mesenchymal stem cell treatments do not require anti-rejection medication, and you do not need to take any special drug before or after your application to prevent an immune reaction.

Can I receive cells from a different donor in a second treatment? Yes. No matching is needed for the first or for later applications.

Are exosomes matched? No. Exosomes derived from umbilical cord MSCs do not require a blood type match either.

Could my body attack the cells over time? The cells act largely through the signals they release, which help regulate inflammation and support repair. Their benefit does not depend on staying in your body permanently.

Questions to ask your doctor

• Is there anything in my medical history that affects how I may respond?
• Should I adjust any immune-related medication before treatment?
• What reactions should I watch for after my treatment?
• How will we follow up on my progress?

Bottom line

You do not need a blood type or DNA match to receive our Wharton's jelly mesenchymal stem cells. They have low immunogenicity, lack HLA-DR and release signals that help regulate the immune response, so rejection like an organ transplant is not expected. Large safety reviews report transient fever as the most frequent related event. Results vary between patients, and no treatment can guarantee a specific outcome. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your condition, goals and medical history.